SHPG - Shire plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
178.38
-1.60 (-0.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close179.98
Open178.44
Bid139.79 x 800
Ask189.90 x 1000
Day's Range178.15 - 179.79
52 Week Range123.73 - 181.41
Volume513,079
Avg. Volume777,326
Market Cap52.872B
Beta1.30
PE Ratio (TTM)11.27
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.06 (0.60%)
Ex-Dividend Date2018-09-06
1y Target EstN/A
Trade prices are not sourced from all markets
  • 4 Stocks John Paulson and Paul Tudor Jones Agree On
    GuruFocus.com14 hours ago

    4 Stocks John Paulson and Paul Tudor Jones Agree On

    Gurus see value in 2 pharmaceutical companies, a chipmaker and an asset manager

  • Is Shire (SHPG) a Suitable Stock for Value Investors Now?
    Zacks18 hours ago

    Is Shire (SHPG) a Suitable Stock for Value Investors Now?

    Let's see if Shire plc (SHPG) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

  • Benzinga19 hours ago

    The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 20.) Abbott Laboratories (NYSE: ABT ) Acceleron ...

  • Company News For Sep 17, 2018
    Zacks5 days ago

    Company News For Sep 17, 2018

    Companies In The News are: ADBE,LB,NI,SHPG

  • Takeda gets China's approval for $62 billion Shire purchase
    Reuters8 days ago

    Takeda gets China's approval for $62 billion Shire purchase

    The acquisition, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from U.S. and Brazilian regulators and awaits approval from Japan and the European Union. Takeda expects the deal to close in the first half of 2019. Takeda's stock is down 15 percent since the company first said it was considering a bid for Shire, with investors concerned about the heavy debt burden the deal will impose on the drugmaker.

  • Takeda gets China's approval for $62 billion Shire purchase
    Reuters8 days ago

    Takeda gets China's approval for $62 billion Shire purchase

    The acquisition, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from U.S. and Brazilian regulators and awaits approval from Japan and the European Union. Takeda expects the deal to close in the first half of 2019. Takeda's stock is down 15 percent since the company first said it was considering a bid for Shire, with investors concerned about the heavy debt burden the deal will impose on the drugmaker.

  • Takeda weighs sale of Shire's eye care business to cut debt: Bloomberg
    Reuters9 days ago

    Takeda weighs sale of Shire's eye care business to cut debt: Bloomberg

    Japan's Takeda Pharmaceutical is considering selling Shire Plc's eye care business once it closes its $62 billion purchase of the London-listed drugmaker, as it looks to cut the debt raised to fund the ...

  • Takeda weighs sale of Shire's eye care business to cut debt - Bloomberg
    Reuters9 days ago

    Takeda weighs sale of Shire's eye care business to cut debt - Bloomberg

    (Reuters) - Japan's Takeda Pharmaceutical is considering selling Shire Plc's (SHP.L) eye care business once it closes its $62 billion (47 billion pounds) purchase of the London-listed drugmaker, as it ...

  • Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt
    Bloomberg9 days ago

    Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt

    Takeda Pharmaceutical Co. is weighing the sale of a Shire Plc eye care business once its $62 billion purchase of the U.K.-listed biotech firm is completed, as it seeks ways to cut the debt raised to fund the deal, people familiar with the matter said. The Xiidra drug, used to treat dry eye disease, is among potential divestments being assessed by Takeda, according to the people, who asked not to be identified because the matter is private. Takeda has also been discussing with banks about a possible sale of Shire’s Natpara medicine, used to control low blood calcium levels related to decreased parathyroid hormone, the people said.

  • Takeda to pack up Illinois HQ, nearly 1,000 workers to be affected
    Reuters10 days ago

    Takeda to pack up Illinois HQ, nearly 1,000 workers to be affected

    The Deerfield site employs just under 1,000 people — about a fifth of its U.S. employees — and a number of them will be provided with job offers and/or relocation opportunities, a Takeda spokeswoman told Reuters on Wednesday. "This move, while difficult, will allow closer collaboration across Takeda to best position our future pipeline for success. In May, Takeda agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion), a deal that will make the firm closer to becoming a top 10 global drugmaker.

  • Shire backs out of deal to lease iconic Genzyme building in Cambridge
    American City Business Journals10 days ago

    Shire backs out of deal to lease iconic Genzyme building in Cambridge

    The surprising move frees up a prime piece of real estate in the red-hot biotech market of Kendall Square. “This space will be very, very competitive," said the director of research for Colliers International in Boston.

  • Shire's ADHD Portfolio Remains Strong Amid Competition
    Zacks11 days ago

    Shire's ADHD Portfolio Remains Strong Amid Competition

    Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.

  • Benzinga25 days ago

    The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks hitting 52-week highs on Aug. 27) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...

  • Shire wins FDA approval for potential blockbuster rare disease drug
    American City Business Journals29 days ago

    Shire wins FDA approval for potential blockbuster rare disease drug

    The approval on Thursday evening is also positive news for Takeda, which is in the process of purchasing Shire for $62 billion.

  • Reuters29 days ago

    European shares steady as trade talks prompt caution

    European shares were steady on Friday as investors were cautious after the latest round of U.S.-China trade talks yielded no breakthrough. The pan-European STOXX 600 (.STOXX) ended the session up 0.1 percent, in a thinner-than-usual market in terms of volume. "Markets are not very directional today," wrote ActivTrades analyst Pierre Veyret, noting that "the U.S. and China have disappointed investors".

  • Shire's Takhzyro Gets FDA Nod for Hereditary Angioedema
    Zacks29 days ago

    Shire's Takhzyro Gets FDA Nod for Hereditary Angioedema

    Shire???s (SHPG) Takhzyro gets approval from the FDA for the treatment of hereditary angioedema in patients 12 years of age and older. It is the first-of-its-kind mAb preventive treatment for the same.

  • One less hurdle for Shire and Takeda tie-up after potential blockbuster drug wins FDA approval
    The Telegraph29 days ago

    One less hurdle for Shire and Takeda tie-up after potential blockbuster drug wins FDA approval

    One less hurdle for Shire and Takeda tie-up after potential blockbuster drug wins FDA approval

  • Reuters29 days ago

    Oil stocks, miners prop FTSE up as markets await Powell

    By Helen Reid LONDON (Reuters) - Britain's major stock index faltered on Friday, propped up by Shire and oil stocks, while investors awaited a speech by the U.S. Fed Chair and digested U.S.-China trade ...

  • Reuters29 days ago

    FDA approves Shire drug for rare swelling disorder

    The drug, Takhzyro, is expected to bring in blockbuster sales for Shire, and is important to Japan's Takeda Pharmaceutical Co Ltd , which plans to buy the Dublin-based rare disease specialist for $62 billion. The monoclonal antibody, previously known by its chemical name lanadelumab, was approved https://www.fda.gov/Drugs/DrugSafety/ucm618261.htm?utm_campaign=FDA%20approves%20new%20treatment%20for%20hereditary%20angioedema%20%28HAE%29&utm_medium=email&utm_source=Eloqua to treat patients with types I and II hereditary angioedema (HAE), a disease that affects about 1 in 50,000. There are only a handful of treatments available for HAE, including some from Shire.

  • Reuters29 days ago

    FDA approves Shire drug for rare swelling disorder

    The U.S. Food and Drug Administration on Thursday approved a first of its kind drug from Shire Plc to treat patients aged 12 and older suffering from a rare hereditary disease that causes swelling. The drug, Takhzyro, is expected to bring in blockbuster sales for Shire, and is important to Japan's Takeda Pharmaceutical Co Ltd, which plans to buy the Dublin-based rare disease specialist for $62 billion. The monoclonal antibody, previously known by its chemical name lanadelumab, was approved https://www.fda.gov/Drugs/DrugSafety/ucm618261.htm?utm_campaign=FDA%20approves%20new%20treatment%20for%20hereditary%20angioedema%20%28HAE%29&utm_medium=email&utm_source=Eloqua to treat patients with types I and II hereditary angioedema (HAE), a disease that affects about 1 in 50,000.

  • Shire, Shionogi File NDA for Intuniv for Adults in Japan
    Zackslast month

    Shire, Shionogi File NDA for Intuniv for Adults in Japan

    Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

  • Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
    Zackslast month

    Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

    Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SHP.L earnings conference call or presentation 31-Jul-18 1:00pm GMT

    Q2 2018 Shire PLC Earnings Call

  • Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2
    Zacks2 months ago

    Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2

    During the second quarter of 2018, the boards of Takeda and Shire (SHPG) reached an agreement pursuant to which the former will acquire the entire issued and to-be-issued ordinary share capital of the latter.